{"abstract":"This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive evaluation option license to practice the inventions embodied in U.S. Patent Application 61/042,239 entitled \"Human Monoclonal Antibodies Specific for CD22\" [HHS Ref. E-080-2008/0-US-01], PCT Application PCT/US2009/124109 entitled \"Human and Improved Murine Monoclonal Antibodies Against CD22\" [HHS Ref. E-080-2008/0-PCT-02], U.S. patent application 12/934,214 entitled \"Human Monoclonal Antibodies Specific for CD22\" [HHS Ref. E-080-2008/0-US-03], and all related continuing and foreign patents/patent applications for the technology family, to Sanomab, Ltd. The patent rights in these inventions have been assigned to and/or exclusively licensed to the Government of the United States of America. The prospective exclusive evaluation option license territory may be worldwide, and the field of use may be limited to:","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2012/02/17/2012-3829.html","cfr_references":[],"citation":"77 FR 9678","comment_url":null,"comments_close_on":"2012-03-05","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before March 5, 2012 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2012-3829","effective_on":null,"end_page":9679,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2012/02/17/2012-3829.xml","html_url":"https://www.federalregister.gov/documents/2012/02/17/2012-3829/prospective-grant-of-exclusive-license-the-development-of-human-anti-cd22-monoclonal-antibodies-for","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2012-3829?publication_date=2012-02-17","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2012-02-17/2012-3829/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":82,"last_updated":"2026-09-23 06:15:06 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2012-02-17/pdf/2012-3829.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2012-03829.pdf?1329400413","publication_date":"2012-02-17","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2012/02/17/2012-3829.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=NIH_FRDOC_0001","supporting_documents_count":0,"docket_id":"NIH_FRDOC_0001","regulation_id_number":null,"title":"Recently Posted NIH Rules and Notices.","checked_regulationsdotgov_at":"2012-04-13T23:44:17Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":9678,"subtype":null,"title":"Prospective Grant of Exclusive License: The Development of Human Anti-CD22 Monoclonal Antibodies for the Treatment of Human Cancers and Autoimmune Disease","toc_doc":"Development of Human Anti-CD22 Monoclonal Antibodies for Treatment of Human Cancers and Autoimmune Disease","toc_subject":"Prospective Grant of Exclusive License:","topics":[],"type":"Notice","volume":77}